Myeloperoxidase News and Research

RSS

Myeloperoxidase (MPO) is a peroxidase enzyme most abundantly present in neutrophil granulocytes (a subtype of white blood cells). It is a lysosomal protein stored in azurophilic granules of the neutrophil. MPO has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus.

Research identifies new pathway to target with anti-inflammatory drugs

Scientists' discovery of an important step in the body's process for healing wounds may lead to a new way of treating inflammation.

31 Aug 2012

ANCA-associated vasculitis not a single clinical entity

Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.

25 Jul 2012

CHL completes $18.4-million Series B financing round

Cleveland HeartLab Inc. (CHL), a leading specialty clinical laboratory and disease management company, today announced the completion of an $18.4-million Series B financing round.

23 Aug 2011

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.

1 Feb 2011

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

20 Dec 2010

OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.

7 Dec 2010

Ergothioneine international congress 2011 to be held at UCLA

OXIS International, Inc., today announced that the "First International Congress on Ergothioneine, Anti-Oxidants, and Age Management Medicine" will be held Friday to Sunday, July 15-17, 2011, in the DeNeve Auditorium at the University of California, Los Angeles.

23 Nov 2010

Study reveals two enzymes help immune cells deploy pathogen-killing traps

A new study reveals that two enzymes help immune cells deploy pathogen-killing traps by unraveling and using the chromatin (DNA and its associated proteins) contained in the cells' nuclei to form defensive webs. The study appears online on October 25 in The Journal of Cell Biology.

26 Oct 2010

Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

OXIS INTERNATIONAL, INC. and THE ESTEE LAUDER COMPANIES INC. announce today that they have resolved a dispute between an Estee Lauder subsidiary, Applied Genetics Incorporated Dermatics, and Oxis over technology related to U.S. Patent No. 6,103,746 and U.S. Patent No. 6,479,533, entitled "Methods and Compositions for the Protection of Mitochondria."

7 Sep 2010

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date).

26 Aug 2010

OXIS International to introduce new ergothioneine-based products for joint health and healthy aging

OXIS INTERNATIONAL, INC. is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel.

25 Aug 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells.

6 Apr 2010

Scientists show carbon nanotubes can be broken down by MPO

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase - found in white blood cells. Their discoveries are presented in Nature Nanotechnology and contradict what was previously believed, that carbon nanotubes are not broken down in the body or in nature.

5 Apr 2010

Mortality in CAD patients: Key predictor identified

Coronary Artery Disease (CAD) hospitalizes more than 160,000 Canadians every year, and almost one quarter of those patients die from this common form of heart disease. But now a team of Vancouver-based researchers has identified a key predictor of mortality in CAD patients, which means that specialists can better determine how to treat and improve outcomes for patients with CAD.

16 Mar 2010

Ergoplex, an anti-inflammatory product, receives good response in direct mail test

OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that Ergoplex™, its commercial anti-inflammatory product using its patented compound, Ergothioneine, a powerful antioxidant, has shown very good acceptance in a recent direct mail test.

29 Oct 2009

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Ore Pharmaceuticals Inc., announced today the publication of an article in the online version of the journal Inflammation Research titled, “Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.”

10 Sep 2009

Radical blow for snotty arteries

Controlling the green stuff in snot could help treat heart disease, reveals Professor Michael Davies from the University of Sydney Faculty of Medicine and the Heart Research Institute.

12 May 2009

Injected luminol glows blue revealing immune cells' misdeeds

Detectives on television shows often spray crime scenes with a compound called luminol to make blood glow.

22 Mar 2009

New biomarkers in acute cardiac care

In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.

1 Sep 2008